Recent studies have reported that chromosomal rearrangements in gliomas resulting in transcript fusion gene, such as NTRK 1/2/3 or FGFR1/2/3 fusions, could be therapeutic targets [15] and are implicated in clinical trials (Entrectinib [15] or Larotrectinib in pediatric patients [19]). The gene discussed is FGFR1; the disease is glioma.